{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:05:59Z","timestamp":1788998759236,"version":"build-2803163510"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100012155","name":"National Institute for Medical Research Development","doi-asserted-by":"publisher","award":["National Institute for Medical Research Development"],"award-info":[{"award-number":["National Institute for Medical Research Development"]}],"id":[{"id":"10.13039\/501100012155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nutr"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00394-025-03618-9","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T09:30:55Z","timestamp":1740475855000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The efficacy and safety of berberine in combination with cinnamon supplementation in patients with type 2 diabetes: a randomized clinical trial"],"prefix":"10.1007","volume":"64","author":[{"given":"Asieh","family":"Mansour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayed Mahmoud","family":"Sajjadi-Jazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadis","family":"Gerami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atie Sadat","family":"Khorasanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnam","family":"Moalemzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima Mohamadi","family":"Afrakoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Mofid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Reza","family":"Mohajeri-Tehrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1944-0052","authenticated-orcid":false,"given":"Azita","family":"Hekmatdoost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"3618_CR1","doi-asserted-by":"crossref","first-page":"154838","DOI":"10.1016\/j.metabol.2021.154838","volume":"123","author":"J-S Yun","year":"2021","unstructured":"Yun J-S, Ko S-H (2021) Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes. Metabolism 123:154838","journal-title":"Metabolism"},{"key":"3618_CR2","doi-asserted-by":"crossref","first-page":"503437","DOI":"10.1016\/j.mrgentox.2021.503437","volume":"874","author":"JE Lima","year":"2022","unstructured":"Lima JE, Moreira NC, Sakamoto-Hojo ET (2022) Mechanisms underlying the pathophysiology of type 2 diabetes: from risk factors to oxidative stress, metabolic dysfunction, and hyperglycemia. Mutat Research\/Genetic Toxicol Environ Mutagen 874:503437","journal-title":"Mutat Research\/Genetic Toxicol Environ Mutagen"},{"key":"3618_CR3","doi-asserted-by":"crossref","first-page":"109118","DOI":"10.1016\/j.diabres.2021.109118","volume":"183","author":"K Ogurtsova","year":"2022","unstructured":"Ogurtsova K, Guariguata L, Barengo NC, Ruiz PL-D, Sacre JW, Karuranga S et al (2022) IDF Diabetes Atlas: global estimates of undiagnosed diabetes in adults for 2021. Diabetes Res Clin Pract 183:109118","journal-title":"Diabetes Res Clin Pract"},{"key":"3618_CR4","doi-asserted-by":"crossref","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB et al (2022) IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 183:109119","journal-title":"Diabetes Res Clin Pract"},{"key":"3618_CR5","doi-asserted-by":"crossref","unstructured":"Taylor SI, Yazdi ZS, Beitelshees AL (2021) Pharmacological treatment of hyperglycemia in type 2 diabetes. J Clin Investig.;131(2)","DOI":"10.1172\/JCI142243"},{"issue":"2","key":"3618_CR6","first-page":"114","volume":"6","author":"S Nimesh","year":"2018","unstructured":"Nimesh S, Ashwlayan V (2018) Nutraceuticals in the management of diabetes mellitus. Pharm Pharmacol Int J 6(2):114\u2013120","journal-title":"Pharm Pharmacol Int J"},{"issue":"3","key":"3618_CR7","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2169\/internalmedicine.54.2745","volume":"54","author":"Q-H Gong","year":"2015","unstructured":"Gong Q-H, Kang J-F, Ying Y-Y, Li H, Zhang X-H, Wu Y-H et al (2015) Lifestyle interventions for adults with impaired glucose tolerance: a systematic review and meta-analysis of the effects on glycemic control. Intern Med 54(3):303\u2013310","journal-title":"Intern Med"},{"issue":"1","key":"3618_CR8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1507\/endocrj.EJ18-0109","volume":"66","author":"Y Liang","year":"2019","unstructured":"Liang Y, Xu X, Yin M, Zhang Y, Huang L, Chen R et al (2019) Effects of berberine on blood glucose in patients with type 2 diabetes mellitus: a systematic literature review and a meta-analysis. Endocr J 66(1):51\u201363","journal-title":"Endocr J"},{"issue":"5","key":"3618_CR9","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1370\/afm.1517","volume":"11","author":"RW Allen","year":"2013","unstructured":"Allen RW, Schwartzman E, Baker WL, Coleman CI, Phung OJ (2013) Cinnamon use in type 2 diabetes: an updated systematic review and meta-analysis. Annals Family Med 11(5):452\u2013459","journal-title":"Annals Family Med"},{"key":"3618_CR10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.phrs.2018.05.015","volume":"134","author":"A Poli","year":"2018","unstructured":"Poli A, Barbagallo CM, Cicero AF, Corsini A, Manzato E, Trimarco B et al (2018) Nutraceuticals and functional foods for the control of plasma cholesterol levels. An intersociety position paper. Pharmacol Res 134:51\u201360","journal-title":"Pharmacol Res"},{"issue":"9","key":"3618_CR11","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.metabol.2014.05.013","volume":"63","author":"Y Wang","year":"2014","unstructured":"Wang Y, Yi X, Ghanam K, Zhang S, Zhao T, Zhu X (2014) Berberine decreases cholesterol levels in rats through multiple mechanisms, including inhibition of cholesterol absorption. Metabolism 63(9):1167\u20131177","journal-title":"Metabolism"},{"issue":"1","key":"3618_CR12","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1038\/s41467-021-25952-2","volume":"12","author":"M-M Zhao","year":"2021","unstructured":"Zhao M-M, Lu J, Li S, Wang H, Cao X, Li Q et al (2021) Berberine is an insulin secretagogue targeting the KCNH6 potassium channel. Nat Commun 12(1):5616","journal-title":"Nat Commun"},{"key":"3618_CR13","doi-asserted-by":"crossref","first-page":"720866","DOI":"10.3389\/fphar.2021.720866","volume":"12","author":"X Lv","year":"2021","unstructured":"Lv X, Zhao Y, Yang X, Han H, Ge Y, Zhang M et al (2021) Berberine potentiates insulin secretion and prevents \u03b2-cell dysfunction through the miR-204\/SIRT1 signaling pathway. Front Pharmacol 12:720866","journal-title":"Front Pharmacol"},{"key":"3618_CR14","doi-asserted-by":"crossref","first-page":"110984","DOI":"10.1016\/j.biopha.2020.110984","volume":"133","author":"X Xu","year":"2021","unstructured":"Xu X, Yi H, Wu J, Kuang T, Zhang J, Li Q et al (2021) Therapeutic effect of berberine on metabolic diseases: both pharmacological data and clinical evidence. Biomed Pharmacother 133:110984","journal-title":"Biomed Pharmacother"},{"key":"3618_CR15","doi-asserted-by":"crossref","first-page":"107815","DOI":"10.1016\/j.diabres.2019.107815","volume":"156","author":"S Deyno","year":"2019","unstructured":"Deyno S, Eneyew K, Seyfe S, Tuyiringire N, Peter EL, Muluye RA et al (2019) Efficacy and safety of cinnamon in type 2 diabetes mellitus and pre-diabetes patients: a meta-analysis and meta-regression. Diabetes Res Clin Pract 156:107815","journal-title":"Diabetes Res Clin Pract"},{"key":"3618_CR16","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s13340-015-0218-y","volume":"7","author":"C Sengsuk","year":"2016","unstructured":"Sengsuk C, Sanguanwong S, Tangvarasittichai O, Tangvarasittichai S (2016) Effect of cinnamon supplementation on glucose, lipids levels, glomerular filtration rate, and blood pressure of subjects with type 2 diabetes mellitus. Diabetol Int 7:124\u2013132","journal-title":"Diabetol Int"},{"issue":"3","key":"3618_CR17","doi-asserted-by":"crossref","first-page":"155932582312005","DOI":"10.1177\/15593258231200527","volume":"21","author":"SN Mohsin","year":"2023","unstructured":"Mohsin SN, Saleem F, Humayun A, Tanweer A, Muddassir A (2023) Prospective Nutraceutical effects of Cinnamon Derivatives against Insulin Resistance in type II diabetes Mellitus\u2014evidence from the literature. Dose-Response 21(3):15593258231200527","journal-title":"Dose-Response"},{"issue":"20","key":"3618_CR18","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.3390\/foods12203852","volume":"12","author":"Y Liu","year":"2023","unstructured":"Liu Y, Liu F, Xing D, Wang W, Yang Q, Liao S et al (2023) Effects of cinnamon powder on glucose metabolism in diabetic mice and the molecular mechanisms. Foods 12(20):3852","journal-title":"Foods"},{"issue":"Supplement1","key":"3618_CR19","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.2337\/dc22-S002","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2022","unstructured":"American Diabetes Association Professional Practice Committee (2022) Classification and diagnosis of diabetes: standards of Medical Care in Diabetes. Diabetes Care 45(Supplement1):S17\u2013S38","journal-title":"Diabetes Care"},{"issue":"8","key":"3618_CR20","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1249\/01.MSS.0000078924.61453.FB","volume":"35","author":"CL Craig","year":"2003","unstructured":"Craig CL, Marshall AL, Sj\u00f6str\u00f6m M, Bauman AE, Booth ML, Ainsworth BE et al (2003) International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 35(8):1381\u20131395","journal-title":"Med Sci Sports Exerc"},{"issue":"4","key":"3618_CR21","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/schbul\/sbj075","volume":"32","author":"DI Velligan","year":"2006","unstructured":"Velligan DI, Lam Y-WF, Glahn DC, Barrett JA, Maples NJ, Ereshefsky L et al (2006) Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull 32(4):724\u2013742","journal-title":"Schizophr Bull"},{"issue":"2","key":"3618_CR22","first-page":"51","volume":"7","author":"W Xiang","year":"2011","unstructured":"Xiang W, Huang X, Huang G (2011) Research on the therapeutic effect of two kinds of anti-inflammatory drugs in newly diagnosed type 2 diabetic patients. J Practical Diabetol 7(2):51\u201352","journal-title":"J Practical Diabetol"},{"key":"3618_CR23","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s11684-019-0724-6","volume":"14","author":"D Song","year":"2020","unstructured":"Song D, Hao J, Fan D (2020) Biological properties and clinical applications of berberine. Front Med 14:564\u2013582","journal-title":"Front Med"},{"issue":"11","key":"3618_CR24","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/toxins12110713","volume":"12","author":"A Och","year":"2020","unstructured":"Och A, Podg\u00f3rski R, Nowak R (2020) Biological activity of berberine\u2014A summary update. Toxins 12(11):713","journal-title":"Toxins"},{"issue":"12","key":"3618_CR25","first-page":"711","volume":"8","author":"Y Ni","year":"1988","unstructured":"Ni Y (1988) Therapeutic effect of berberine on 60 patients with type II diabetes mellitus and experimental research. Zhong Xi Yi Jie he za zhi = Chinese. J Mod Developments Traditional Med 8(12):711\u2013713","journal-title":"J Mod Developments Traditional Med"},{"key":"3618_CR26","first-page":"4734","volume":"13","author":"W Xie","year":"2022","unstructured":"Xie W, Su F, Wang G, Peng Z, Xu Y, Zhang Y et al (2022) Glucose-lowering effect of berberine on type 2 diabetes: a systematic review and meta-analysis. Front Pharmacol 13:4734","journal-title":"Front Pharmacol"},{"key":"3618_CR27","doi-asserted-by":"crossref","first-page":"1013055","DOI":"10.3389\/fnut.2022.1013055","volume":"9","author":"M Zamani","year":"2022","unstructured":"Zamani M, Zarei M, Nikbaf-Shandiz M, Hosseini S, Shiraseb F, Asbaghi O (2022) The effects of berberine supplementation on cardiovascular risk factors in adults: a systematic review and dose-response meta-analysis. Front Nutr 9:1013055","journal-title":"Front Nutr"},{"key":"3618_CR28","first-page":"885","volume":"12","author":"Y Ye","year":"2021","unstructured":"Ye Y, Liu X, Wu N, Han Y, Wang J, Yu Y et al (2021) Efficacy and safety of berberine alone for several metabolic disorders: a systematic review and meta-analysis of randomized clinical trials. Front Pharmacol 12:885","journal-title":"Front Pharmacol"},{"key":"3618_CR29","doi-asserted-by":"crossref","unstructured":"Guo J, Chen H, Zhang X, Lou W, Zhang P, Qiu Y et al (2021) The effect of berberine on metabolic profiles in type 2 diabetic patients: A systematic review and meta-analysis of randomized controlled trials. Oxidative Medicine and Cellular Longevity.;2021","DOI":"10.1155\/2021\/2074610"},{"key":"3618_CR30","doi-asserted-by":"crossref","unstructured":"Rashidi H, Namjoyan F, Mehraban Z, Zakerkish M, Ghaderian SB, Latifi SM (2018) The effects of active ingredients of barberry root (Berberine) on glycemic control and insulin resistance in type 2 diabetic patients. Jundishapur J Nat Pharm Prod.;13(1)","DOI":"10.5812\/jjnpp.64180"},{"key":"3618_CR31","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s40200-019-00478-z","volume":"19","author":"M Sanjari","year":"2020","unstructured":"Sanjari M, Shamsinejad B, Khazaeli P, Safi Z, Mirrashidi F, Naghibzadeh-Tahami A (2020) Safety and efficacy of Berberis integerrima root extract in patients with type 2 diabetes. A parallel intervention based triple blind clinical trial. J Diabetes Metabolic Disorders 19:71\u201380","journal-title":"J Diabetes Metabolic Disorders"},{"issue":"6","key":"3618_CR32","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1194\/jlr.M600020-JLR200","volume":"47","author":"J-M Brusq","year":"2006","unstructured":"Brusq J-M, Ancellin N, Grondin P, Guillard R, Martin S, Saintillan Y et al (2006) Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J Lipid Res 47(6):1281\u20131288","journal-title":"J Lipid Res"},{"key":"3618_CR33","doi-asserted-by":"crossref","unstructured":"Zhang Q, Xiao X, Feng K, Wang T, Li W, Yuan T et al (2010) Berberine moderates glucose and lipid metabolism through multipathway mechanism. Evidence-Based Complementary and Alternative Medicine.;2011","DOI":"10.1155\/2011\/924851"},{"issue":"4","key":"3618_CR34","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1177\/2156587216687695","volume":"22","author":"LM Koppen","year":"2017","unstructured":"Koppen LM, Whitaker A, Rosene A, Beckett RD (2017) Efficacy of berberine alone and in combination for the treatment of hyperlipidemia: a systematic review. J Evidence-Based Complement Altern Med 22(4):956\u2013968","journal-title":"J Evidence-Based Complement Altern Med"},{"key":"3618_CR35","doi-asserted-by":"crossref","unstructured":"Li X, Qiao B, Wu Y, Deng N, Tan Z (2023) Evaluation of toxicological effects of chemical substances by gut microbiota: the example of adenine damage to the kidney and gut. Heliyon.;9(12)","DOI":"10.1016\/j.heliyon.2023.e23010"},{"issue":"15","key":"3618_CR36","doi-asserted-by":"crossref","first-page":"8074","DOI":"10.3390\/ijms22158074","volume":"22","author":"M Vourakis","year":"2021","unstructured":"Vourakis M, Mayer G, Rousseau G (2021) The role of gut microbiota on cholesterol metabolism in atherosclerosis. Int J Mol Sci 22(15):8074","journal-title":"Int J Mol Sci"},{"key":"3618_CR37","doi-asserted-by":"crossref","first-page":"1354823","DOI":"10.3389\/fmicb.2024.1354823","volume":"15","author":"M Guo","year":"2024","unstructured":"Guo M, Fang L, Chen M, Shen J, Tan Z, He W (2024) Dysfunction of cecal microbiota and CutC activity in mice mediating diarrhea with kidney-Yang deficiency syndrome. Front Microbiol 15:1354823","journal-title":"Front Microbiol"},{"key":"3618_CR38","doi-asserted-by":"crossref","first-page":"864600","DOI":"10.3389\/fcvm.2022.864600","volume":"9","author":"L Jing","year":"2022","unstructured":"Jing L, Zhang H, Xiang Q, Shen L, Guo X, Zhai C et al (2022) Targeting trimethylamine N-oxide: a new therapeutic strategy for alleviating atherosclerosis. Front Cardiovasc Med 9:864600","journal-title":"Front Cardiovasc Med"},{"key":"3618_CR39","doi-asserted-by":"crossref","first-page":"1324938","DOI":"10.3389\/fmicb.2023.1324938","volume":"14","author":"M Zhou","year":"2024","unstructured":"Zhou M, Li X, Wang X, Deng N, Cai Y, Tan Z (2024) The dysfunction in intestinal microorganisms and enzyme activity as significant contributors to diarrhea with kidney-Yang deficiency syndrome. Front Microbiol 14:1324938","journal-title":"Front Microbiol"},{"key":"3618_CR40","doi-asserted-by":"crossref","first-page":"1271001","DOI":"10.3389\/fphar.2023.1271001","volume":"14","author":"Y Feng","year":"2023","unstructured":"Feng Y, Xu D (2023) Short-chain fatty acids are potential goalkeepers of atherosclerosis. Front Pharmacol 14:1271001","journal-title":"Front Pharmacol"},{"issue":"3","key":"3618_CR41","doi-asserted-by":"crossref","first-page":"892","DOI":"10.3390\/nu13030892","volume":"13","author":"S Shah","year":"2021","unstructured":"Shah S, Fillier T, Pham TH, Thomas R, Cheema SK (2021) Intraperitoneal administration of short-chain fatty acids improves lipid metabolism of long\u2013evans rats in a sex-specific manner. Nutrients 13(3):892","journal-title":"Nutrients"},{"key":"3618_CR42","doi-asserted-by":"crossref","first-page":"1283784","DOI":"10.3389\/fphar.2023.1283784","volume":"14","author":"Y Cai","year":"2023","unstructured":"Cai Y, Yang Q, Yu Y, Yang F, Bai R, Fan X (2023) Efficacy and underlying mechanisms of berberine against lipid metabolic diseases: a review. Front Pharmacol 14:1283784","journal-title":"Front Pharmacol"},{"issue":"1","key":"3618_CR43","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41392-022-01027-6","volume":"7","author":"S-R Ma","year":"2022","unstructured":"Ma S-R, Tong Q, Lin Y, Pan L-B, Fu J, Peng R et al (2022) Berberine treats atherosclerosis via a vitamine-like effect down-regulating Choline-TMA-TMAO production pathway in gut microbiota. Signal Transduct Target Therapy 7(1):207","journal-title":"Signal Transduct Target Therapy"},{"key":"3618_CR44","doi-asserted-by":"crossref","unstructured":"Qu H, Zhang Y, Shi J-h, Zhao Y-h, Gao J, Gao Z-y et al (2024) Berberine decreases thrombosis potential Induced by a high-choline Diet by inhibiting CutC enzyme. Curr Med Chem","DOI":"10.2174\/0929867330666230524142632"},{"key":"3618_CR45","doi-asserted-by":"crossref","first-page":"709629","DOI":"10.3389\/fphar.2021.709629","volume":"12","author":"S Yang","year":"2021","unstructured":"Yang S, Li D, Yu Z, Li Y, Wu M (2021) Multi-pharmacology of berberine in atherosclerosis and metabolic diseases: potential contribution of gut microbiota. Front Pharmacol 12:709629","journal-title":"Front Pharmacol"},{"issue":"2","key":"3618_CR46","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","volume":"110","author":"SM Grundy","year":"2004","unstructured":"Grundy SM, Cleeman JI, Merz CNB, Brewer HB Jr, Clark LT, Hunninghake DB et al (2004) Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 110(2):227\u2013239","journal-title":"Circulation"},{"issue":"5","key":"3618_CR47","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40265-023-01841-4","volume":"83","author":"JE Blais","year":"2023","unstructured":"Blais JE, Huang X, Zhao JV (2023) Overall and sex-specific effect of Berberine for the Treatment of Dyslipidemia in adults: a systematic review and Meta-analysis of Randomized Placebo-controlled trials. Drugs 83(5):403\u2013427","journal-title":"Drugs"},{"key":"3618_CR48","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jep.2014.09.049","volume":"161","author":"J Lan","year":"2015","unstructured":"Lan J, Zhao Y, Dong F, Yan Z, Zheng W, Fan J et al (2015) Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol 161:69\u201381","journal-title":"J Ethnopharmacol"},{"issue":"06","key":"3618_CR49","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1055\/s-0032-1328321","volume":"79","author":"H Dong","year":"2013","unstructured":"Dong H, Zhao Y, Zhao L, Lu F (2013) The effects of berberine on blood lipids: a systemic review and meta-analysis of randomized controlled trials. Planta Med 79(06):437\u2013446","journal-title":"Planta Med"},{"issue":"5","key":"3618_CR50","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nrendo.2016.210","volume":"13","author":"PM Hunter","year":"2017","unstructured":"Hunter PM, Hegele RA (2017) Functional foods and dietary supplements for the management of dyslipidaemia. Nat Reviews Endocrinol 13(5):278\u2013288","journal-title":"Nat Reviews Endocrinol"},{"issue":"5","key":"3618_CR51","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3390\/f12050648","volume":"12","author":"N B\u0142aszczyk","year":"2021","unstructured":"B\u0142aszczyk N, Rosiak A, Ka\u0142u\u017cna-Czapli\u0144ska J (2021) The potential role of cinnamon in human health. Forests 12(5):648","journal-title":"Forests"},{"key":"3618_CR52","doi-asserted-by":"crossref","unstructured":"Moridpour AH, Kavyani Z, Khosravi S, Farmani E, Daneshvar M, Musazadeh V et al (2023) The effect of cinnamon supplementation on glycemic control in patients with type 2 diabetes mellitus: an updated systematic review and dose-response meta\u2010analysis of randomized controlled trials. Phytother Res","DOI":"10.1002\/ptr.8026"},{"key":"3618_CR53","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ctim.2019.01.002","volume":"43","author":"N Namazi","year":"2019","unstructured":"Namazi N, Khodamoradi K, Khamechi SP, Heshmati J, Ayati MH, Larijani B (2019) The impact of cinnamon on anthropometric indices and glycemic status in patients with type 2 diabetes: a systematic review and meta-analysis of clinical trials. Complement Ther Med 43:92\u2013101","journal-title":"Complement Ther Med"},{"key":"3618_CR54","doi-asserted-by":"crossref","first-page":"960580","DOI":"10.3389\/fphys.2022.960580","volume":"13","author":"Q Zhou","year":"2022","unstructured":"Zhou Q, Lei X, Fu S, Li Z, Chen Y, Long C et al (2022) Efficacy of cinnamon supplementation on glycolipid metabolism in T2DM diabetes: a meta-analysis and systematic review. Front Physiol 13:960580","journal-title":"Front Physiol"},{"key":"3618_CR55","doi-asserted-by":"crossref","first-page":"102571","DOI":"10.1016\/j.ctim.2020.102571","volume":"55","author":"N Jamali","year":"2020","unstructured":"Jamali N, Kazemi A, Saffari-Chaleshtori J, Samare-Najaf M, Mohammadi V, Clark CC (2020) The effect of cinnamon supplementation on lipid profiles in patients with type 2 diabetes: a systematic review and meta-analysis of clinical trials. Complement Ther Med 55:102571","journal-title":"Complement Ther Med"},{"issue":"1","key":"3618_CR56","doi-asserted-by":"crossref","first-page":"141","DOI":"10.26650\/IstanbulJPharm.2020.0056","volume":"51","author":"A Thomas","year":"2021","unstructured":"Thomas A, Kamble S, Deshkar S, Kothapalli L, Chitlange S (2021) Bioavailability of berberine: challenges and solutions. \u0130stanbul J Pharm 51(1):141\u2013153","journal-title":"\u0130stanbul J Pharm"},{"issue":"4","key":"3618_CR57","doi-asserted-by":"crossref","first-page":"e22720","DOI":"10.1002\/jbt.22720","volume":"35","author":"E Angelopoulou","year":"2021","unstructured":"Angelopoulou E, Paudel YN, Piperi C, Mishra A (2021) Neuroprotective potential of cinnamon and its metabolites in Parkinson\u2019s disease: mechanistic insights, limitations, and novel therapeutic opportunities. J Biochem Mol Toxicol 35(4):e22720","journal-title":"J Biochem Mol Toxicol"},{"issue":"12","key":"3618_CR58","doi-asserted-by":"crossref","first-page":"7540","DOI":"10.1039\/D2RA00044J","volume":"12","author":"B Al Tbakhi","year":"2022","unstructured":"Al Tbakhi B, Nsairat H, Alshaer W, Al-Kadash A, Helal W, Alrawashdeh L et al (2022) Cinnamaldehyde\u2013cucurbituril complex: investigation of loading efficiency and its role in enhancing cinnamaldehyde in vitro anti-tumor activity. RSC Adv 12(12):7540\u20137549","journal-title":"RSC Adv"},{"issue":"8","key":"3618_CR59","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.2337\/dc09-1727","volume":"33","author":"D Sherifali","year":"2010","unstructured":"Sherifali D, Nerenberg K, Pullenayegum E, Cheng JE, Gerstein HC (2010) The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care 33(8):1859\u20131864","journal-title":"Diabetes Care"},{"issue":"1","key":"3618_CR60","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41598-022-27301-9","volume":"13","author":"M Nagao","year":"2023","unstructured":"Nagao M, Sasaki J, Sugihara H, Tanimura-Inagaki K, Harada T, Sakuma I et al (2023) Efficacy and safety of sitagliptin treatment in older adults with moderately controlled type 2 diabetes: the STREAM study. Sci Rep 13(1):134","journal-title":"Sci Rep"},{"issue":"3","key":"3618_CR61","doi-asserted-by":"crossref","first-page":"e00072","DOI":"10.1002\/edm2.72","volume":"2","author":"S Niezen","year":"2019","unstructured":"Niezen S, Diaz del Castillo H, Mendez Castaner LA, Fornoni A (2019) Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease. Endocrinol Diabetes Metabolism 2(3):e00072","journal-title":"Endocrinol Diabetes Metabolism"},{"key":"3618_CR62","doi-asserted-by":"crossref","unstructured":"Black C, Donnelly P, McIntyre L, Royle P, Shepherd JJ, Thomas S Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database Syst Reviews. 2007(2).","DOI":"10.1002\/14651858.CD004654.pub2"}],"container-title":["European Journal of Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00394-025-03618-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00394-025-03618-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00394-025-03618-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T13:18:41Z","timestamp":1742217521000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00394-025-03618-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["3618"],"URL":"https:\/\/doi.org\/10.1007\/s00394-025-03618-9","relation":{},"ISSN":["1436-6207","1436-6215"],"issn-type":[{"value":"1436-6207","type":"print"},{"value":"1436-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"21 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"It should be emphasized that Dr. Vahid Mofid is an employee of Pajoohesh Gostran Taghzie asan\n                      \u00ae\n                      Company. Other authors have not conflicts of interest or financial ties to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"102"}}